CHARACTERIZATION OF BINDING-SITES FOR [H-3] IDAZOXAN, [H-3] P-AMINOCLONIDINE AND [H-3] RAUWOLSCINE IN THE KIDNEY OF THE DOG

被引:12
作者
EVANS, RG [1 ]
HAYNES, JM [1 ]
机构
[1] UNIV MELBOURNE,HEIDELBERG REPATRIAT HOSP,DEPT MED,HEIDELBERG,VIC,AUSTRALIA
关键词
DOG; IDAZOXAN; IMIDAZOLINE-PREFERRING RECEPTOR; KIDNEY; P-AMINOCLONIDINE; RADIOLIGAND BINDING; RAUWOLSCINE;
D O I
10.1111/j.1440-1681.1994.tb02566.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. We characterized the binding of[H-3]-rauwolscine, [H-3]-p-aminoclonidine and [H-3]-idazoxan in a dog kidney membrane preparation. Our aim was to determine the pharmacological nature of the alpha(2)-adrenoceptor- and imidazoline-preferring binding sites in this organ. 2. [H-3]-Rauwolscine bound to an apparent single site with an affinity (K-D) of 2.2 nmol/L and a maximum density (B-max) of 58.5 fmol/mg protein, when 10 mu mol/L idazoxan defined non-specific binding. However displacement studies demonstrated that a number of compounds, including prazosin, inhibited [H-3]-rauwolscine binding in a complex manner consistent with displacement from two distinct binding sites. The majority (69%) of the [H-3]-rauwolscine binding sites had a relatively low affinity for prazosin (K-I = 398 nmol/L), while the remainder had a relatively high affinity for prazosin (K-I = 7.9 nmol/L). 3. [H-3]-p-Aminoclonidine bound to an apparent single site (K-D = 5.2 nmol/L; B-max = 72.4 fmol/mg protein), when 10 mu mol/L phentolamine defined non-specific binding. When 1 mu mol/L of the potent and selective alpha(2)-adrenoceptor antagonist 2-methoxyidazoxan was included in the incubate, no specific binding was detected. We therefore conclude that under the conditions of this experiment [H-3]-p-aminoclonidine binds only to alpha(2)-adrenoceptors in the dog kidney. 4. [H-3]-Idazoxan bound to two sites, with a higher(K-D = 0.95 nmol/L; B-max = 43.9 fmol/mg protein) and lower (K-D = 9.1 nmol/L; B-max = 93.8 fmol/mg protein) affinity, respectively, when 1 mmol/L phentolamine defined non-specific binding. When 10 mu mol/L GTP gamma S was included in the incubate, the low affinity site was unaffected but the maximum binding at the higher affinity site was reduced by 79%. 2-Methoxyidazoxan displaced [H-3]-idazoxan in a monophasic manner and with low potency (IC50 = 11.5 mu mol/L). Yohimbine, efaroxan, clonidine, rilmenidine, guanabenz and idazoxan itself displaced [H-3]-idazoxan in a complex manner; the slope of the displacement curves being less than unity. 5. We conclude that the dog kidney contains a heterogeneous population of alpha(2)-adrenoceptors that can be labelled either with [H-3]-rauwolscine or [H-3]-p-aminoclonidine. The dog kidney also contains a heterogeneous population of non-adrenoceptor imidazoline-preferring binding sites of the I-2-subtype, that can be labelled with [H-3]-idazoxan. The binding site for which [H-3]-idazoxan has the highest affinity appears to be coupled to a guanine nucleotide binding regulatory protein.
引用
收藏
页码:649 / 658
页数:10
相关论文
共 47 条
[1]  
BLAXALL HS, 1991, J PHARMACOL EXP THER, V259, P323
[2]   THE IMIDAZOLINE PREFERRING RECEPTOR - BINDING-STUDIES IN BOVINE, RAT AND HUMAN BRAIN-STEM [J].
BRICCA, G ;
DONTENWILL, M ;
MOLINES, A ;
FELDMAN, J ;
BELCOURT, A ;
BOUSQUET, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 162 (01) :1-9
[3]   HETEROGENEITY OF THE SPECIFIC IMIDAZOLINE BINDING OF [H-3] IDAZOXAN IN THE HUMAN CEREBRAL-CORTEX [J].
BRICCA, G ;
GRENEY, H ;
DONTENWILLKIEFFER, M ;
ZHANG, J ;
BELCOURT, A ;
BOUSQUET, P .
NEUROCHEMISTRY INTERNATIONAL, 1993, 22 (02) :153-163
[4]   HUMAN BRAIN IMIDAZOLINE RECEPTORS - FURTHER CHARACTERIZATION WITH [H-3] CLONIDINE [J].
BRICCA, G ;
GRENEY, H ;
ZHANG, JS ;
DONTENWILL, M ;
STUTZMANN, J ;
BELCOURT, A ;
BOUSQUET, P .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 266 (01) :25-33
[5]   HETEROGENEITY OF ALPHA-2-ADRENOCEPTORS IN RAT CORTEX BUT NOT HUMAN PLATELETS CAN BE DEFINED BY 8-OH-DPAT, RU-24969 AND METHYSERGIDE [J].
BROWN, CM ;
MACKINNON, AC ;
MCGRATH, JC ;
SPEDDING, M ;
KILPATRICK, AT .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 99 (03) :481-486
[6]  
BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600
[7]  
BYLUND DB, 1994, PHARMACOL REV, V46, P121
[8]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[9]  
COUPRY I, 1990, J PHARMACOL EXP THER, V252, P293
[10]   (H-3) RAUWOLSCINE BEHAVES AS AN AGONIST FOR THE 5-HT1A RECEPTORS IN HUMAN FRONTAL-CORTEX MEMBRANES [J].
DEVOS, H ;
CZERWIEC, E ;
DEBACKER, JP ;
DEPOTTER, W ;
VAUQUELIN, G .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1991, 207 (01) :1-8